STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway

Leuk Lymphoma. 2016 Nov;57(11):2681-4. doi: 10.3109/10428194.2016.1153089. Epub 2016 Mar 8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aminosalicylic Acids / pharmacology*
  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Lineage / drug effects
  • Cell Lineage / genetics
  • Gene Expression Regulation, Leukemic / drug effects
  • HMGA1a Protein / genetics
  • HMGA1a Protein / metabolism
  • Humans
  • Jurkat Cells
  • Mice
  • Mice, Nude
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology*
  • Precursor Cells, B-Lymphoid / drug effects*
  • Precursor Cells, B-Lymphoid / metabolism
  • Precursor Cells, B-Lymphoid / pathology
  • STAT3 Transcription Factor / antagonists & inhibitors
  • STAT3 Transcription Factor / genetics
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Sulfonamides / pharmacology*
  • Tumor Cells, Cultured
  • Up-Regulation / drug effects
  • Up-Regulation / genetics
  • Xenograft Model Antitumor Assays

Substances

  • Aminosalicylic Acids
  • Antineoplastic Agents
  • BP-1-102
  • STAT3 Transcription Factor
  • Sulfonamides
  • HMGA1a Protein